Skip to content
Screener

Summit Therapeutics SMMT Prepaid & Other Current

Prepaid & Other Current at other companies

Merck & Co. logo
Merck & Co.MRK
$10.77B+7.7%
Immunome logo
ImmunomeIMNM
$11.62M+100%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$9.5M+42.8%
Incyte logo
IncyteINCY
$253.09M-14.4%
Gilead Sciences logo
Gilead SciencesGILD
$3.76B+29.7%
Exelixis logo
ExelixisEXEL
$60.5M-18.1%

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$11.14B-46.9%
Enterprise value$11.15B-46.9%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 5:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001599298-26-000039
Line itemMarch 31, 2026December 31, 2025
Cash and cash equivalents$106,515$225,266
Restricted cash316316
Short-term investments492,216488,182
Prepaid expenses and other current assets17,5516,537
Total current assets616,598720,301
Non-current assets:
Property and equipment, net1,6641,059
Operating lease right-of-use assets19,39820,616

Item 1. Financial Statements.

FAQ

What is Summit Therapeutics's prepaid & other current?
Summit Therapeutics (SMMT) reported prepaid & other current of $17.55M in Q1 2026.
How has Summit Therapeutics's prepaid & other current changed year-over-year?
Summit Therapeutics's prepaid & other current increased by 92.5% year-over-year, from $9.12M to $17.55M.
What is the long-term trend for Summit Therapeutics's prepaid & other current?
Over 5 years (2020 to 2025), Summit Therapeutics's prepaid & other current has grown at a -7.3% compound annual growth rate (CAGR), from $9.55M to $6.54M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.

Ask your AI about Summit Therapeutics's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude